Chinese CDMOs to work together on global mRNA services

25 September 2023

Two Chinese contract development and manufacturing organizations (CDMO) with significant US operations have agreed to collaborate in the growth area of mRNA manufacturing.

Based in Guangzhou, PackGene Biotech is focused on adeno-associated virus (AAV) vectors, offering plasmid DNA and AAV viral vector production for early-stage drug discovery, preclinical development, and clinical trials.

Shanghai-based Kudo Bio, which also has a footprint in Boston, USA, and Singapore, is focused on end-to-end mRNA manufacturing solutions, with a state-of-the-art clinical GMP facility.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK